Treatment with IPI-549 also led to up-regulation of PD-1 and CTLA-4 expression on CD8+ T-cells, suggesting that combining PI3K-γ inhibition with immune checkpoint blockade could provide additional anti-tumor effects. The gene discussed is PDCD1; the disease is neoplasm.